ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Dihydrocapsiate on Adaptive and Diet-Induced Thermogenesis With a High Protein Very Low Calorie Diet

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01142687
Recruitment Status : Completed
First Posted : June 11, 2010
Last Update Posted : November 28, 2016
Sponsor:
Information provided by (Responsible Party):
University of California, Los Angeles

Brief Summary:
The study is designed to determine the effects of a non-pungent supplement from sweet chilli pepper on resting metabolic rate and diet-induced thermogenesis (DIT) after a period of very low calorie intake over 4 weeks.

Condition or disease Intervention/treatment Phase
Healthy Dietary Supplement: dihydrocapsiate capsule Not Applicable

Detailed Description:

Thirty-six subjects will be recruited by public advertisement. Postmenopausal women and men over age 30 with a body mass index (BMI) between 27 to 35 kg/m2,and in good health by history, physical examination, and basic laboratory screening (complete blood count, serum chemistries, liver panel, and lipid panel) will be selected for study. Subjects with type 2 diabetes or glucose intolerance will be excluded as will individuals who regularly drink more than one alcoholic beverage daily. Thirty-six men and women who meet the selection criteria below will be randomly assigned to one of three arms providing CH-19 at two dose levels per day vs. placebo capsules.

This will be a prospectively randomized double blind study in which neither the subjects nor the clinical research personnel will be aware of whether the subjects will be assigned to placebo or dihydrocapsiate at two different doses. A total of 36 subjects will be divided among three groups.

To keep the number of capsules taken by each subject constant, all subjects will take three capsules three times per day containing the appropriate number of active or placebo capsules and will be randomized after screening to one of three groups:

  • Group 1: Dihydrocapsiate 1 capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner.
  • Group 2: Dihydrocapsiate 3 capsules three times per day within 30 minutes before breakfast, lunch and dinner
  • Group 3: Placebo 3 capsules three times per day within 30 minutes before breakfast, lunch and dinner

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 58 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Effects of Dihydrocapsiate on Adaptive and Diet-Induced Thermogenesis Following 4 Weeks of Very Low Calorie Diet
Study Start Date : November 2008
Actual Primary Completion Date : June 2009
Actual Study Completion Date : August 2009

Arm Intervention/treatment
Active Comparator: dihydrocapsiate 3 mg
• Group 1: 1 Dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner
Dietary Supplement: dihydrocapsiate capsule
  • Group 1: 1 dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner.
  • Group 2: 3 dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner
  • Group 3: Placebo 3 capsules three times per day within 30 minutes before breakfast, lunch and dinner
Other Name: chili pepper

Active Comparator: dihydrocapsiate 9 mg
• Group 2: 3 Dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner
Dietary Supplement: dihydrocapsiate capsule
  • Group 1: 1 dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner.
  • Group 2: 3 dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner
  • Group 3: Placebo 3 capsules three times per day within 30 minutes before breakfast, lunch and dinner
Other Name: chili pepper

Placebo Comparator: Placebo capsule
• Group 3: 3 placebo capsules three times per day within 30 minutes before breakfast, lunch and dinner
Dietary Supplement: dihydrocapsiate capsule
  • Group 1: 1 dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner.
  • Group 2: 3 dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner
  • Group 3: Placebo 3 capsules three times per day within 30 minutes before breakfast, lunch and dinner
Other Name: chili pepper




Primary Outcome Measures :
  1. Adaptive Thermogenesis [ Time Frame: 4 weeks ]
    To determine the effects of dihydrocapsiate at two doses on the decrease in resting metabolic rate which occurs after a period of very low calorie intake over 4 weeks


Secondary Outcome Measures :
  1. Diet-Induced thermogenesis [ Time Frame: 4 weeks ]
    To determine the effects of dihydrocapsiate at two doses on diet-induced thermogenesis (DIT) following a 426 Calorie high protein liquid meal



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:a.

  1. Postmenopausal female or male over 30 years of age at the time the consent form is signed.
  2. Subject has a BMI between 27 and 35 kg/m2
  3. Subject is in good health based on history, physical examination, and basic laboratory studies.
  4. Consumes less than one alcoholic beverage per day
  5. Is a non-smoker for at least three months
  6. Willing to follow a Very Low Calorie Diet of 800 calories per day using meal replacements
  7. Ethical: Subject must sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or randomization. A subject will be excluded for any condition that might compromise the ability to give truly informed consent for participation in the study.

Exclusion Criteria:

  1. Any subject with known allergy to chili peppers by history.
  2. Any subject with type 2 diabetes or glucose intolerance
  3. Consumes more than one alcoholic beverage per day
  4. Any subject participating in regular vigorous exercises other than ordinary daily walks or who is unwilling to maintain their usual level of exercise during the study.
  5. Any subject with a diagnosed eating disorder or who is addicted to any medications.
  6. Any subject currently taking antidepressants or weight loss medication.
  7. Any subjects with a history of gastrointestinal surgery, uncontrolled hypertension, or other serious medical condition, such as chronic hepatitis or renal disease, bleeding disorder, congestive heart disease, chronic diarrhea disorders, myocardial infarction, coronary artery bypass graft, angioplasty within 6 months prior to screening, current diagnosis of uncontrolled hypertension (defined as BP >160mmHg, diastolic BP>95mmHg), active or chronic gastrointestinal disorders, bulimia, anorexia, laxative abuse, or endocrine diseases (except thyroid disease requiring medication) as indicated by medical history or routine physical examination.
  8. Major surgery within 12 weeks prior to subject randomization and/or screening, especially cardiac surgery
  9. Is currently a smoker who has a therapeutic plan to quit smoking anytime during the study period; or if not a current smoker, has quit smoking within the past 3 months.
  10. Known HIV positive.
  11. Clinical evidence of current malignancy with the exception of basal cell or squamous cell carcinoma of the skin and cervical intraepithelial neoplasia.
  12. Currently receiving systemic chemotherapy and/or radiotherapy.
  13. Active bleeding.
  14. Subject has any disorder including illiteracy or visual impairment that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.
  15. In the opinion of the study investigator has a risk of non-compliance with study procedures, or cannot read, understand or complete study related materials.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01142687


Sponsors and Collaborators
University of California, Los Angeles
Investigators
Principal Investigator: David Heber, MD, PhD University of California, Los Angeles

Publications of Results:
Responsible Party: University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT01142687     History of Changes
Other Study ID Numbers: 08-05-113
First Posted: June 11, 2010    Key Record Dates
Last Update Posted: November 28, 2016
Last Verified: November 2016

Keywords provided by University of California, Los Angeles:
Resting energy expenditure (REE)
metabolic rate

Additional relevant MeSH terms:
Capsaicin
Antipruritics
Dermatologic Agents
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs